VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Canaccord Genuity Raises Illumina's Price Target to $150, Maintains 'Hold' Rating
Canaccord Genuity Raises Illumina's Price Target to $150, Maintains 'Hold' Rating
Jan 27, 2026 15:49 CST Updated 15:49
Share:
Illumina
Diagnostic Product Developer
Gelonghui January 27 | Canaccord Genuity raised Illumina's target price from $130 to $150 and maintained a "Hold" rating. (Gelonghui)